Judge Signs Off On Final Approval Of $73M Settlement For EpiPen Antitrust Claims

( May 22, 2025, 2:43 PM EDT) -- KANSAS CITY, Kan. — A Kansas federal judge on May 21 granted final approval to a $73 million settlement reached with Mylan NV, Mylan Specialty LP and Mylan Pharmaceuticals Inc. (collectively, Mylan) to end claims that they conspired with others in an attempt to delay entry of generic competitors for the EpiPen XE "EpiPen"  epinephrine autoinjector (EAI) into the market....

Attached Documents

Related Sections